Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per ...

Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from ...

Consumer credit delinquencies rose to the highest levels in five years according to the January 2025 edition of CreditGauge ...

L'Oréal Groupe today announced the completion and grand opening of its new North America Research & Innovation (R&I) Center located in Clark, New Jersey, marking a significant milestone in the company ...

The split will allow WBD to take advantage of "broader market opportunities" as they arise, CEO David Zaslav told analysts.